![cover image](https://wikiwandv2-19431.kxcdn.com/_next/image?url=https://upload.wikimedia.org/wikipedia/commons/thumb/b/b5/Treprostinil.svg/640px-Treprostinil.svg.png&w=640&q=50)
Treprostinil
Chemical compound / From Wikipedia, the free encyclopedia
Treprostinil, sold under the brand names Remodulin for infusion, Orenitram for oral, and Tyvaso for inhalation, is a vasodilator that is used for the treatment of pulmonary arterial hypertension.[6]
This article needs additional citations for verification. (October 2021) |
Quick Facts Clinical data, Trade names ...
![]() | |
![]() | |
Clinical data | |
---|---|
Trade names | Remodulin, Orenitram, Tyvaso, others |
AHFS/Drugs.com | Monograph |
License data |
|
Pregnancy category |
|
Routes of administration | Subcutaneous, intravenous, inhalation, by mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | ~100% |
Metabolism | Substantially metabolized by the liver |
Elimination half-life | 4 hours |
Excretion | Urine (79% of administered dose is excreted as 4% unchanged drug and 64% as identified metabolites); feces (13%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.236.149 ![]() |
Chemical and physical data | |
Formula | C23H34O5 |
Molar mass | 390.520 g·mol−1 |
| |
![]() ![]() |
Close
Treprostinil was approved for use in the United States in May 2002.[7]